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Abstract 
Background: The limbal area of the corneal stroma has been identified as a source of 
mesenchymal-like stem cells, which have potential for exploitation as a cell therapy. 
However, the optimal culture conditions are disputed and few direct media comparisons have 
been performed. In this report, we evaluated several media types to identify the optimal for 
inducing an in vitro stem cell phenotype. 
Methods: Primary human corneal stroma-derived stem cells (CSSC) were extracted from 
corneoscleral rims. Culture in seven different media types was compared: Dulbecco’s 
modified Eagle’s medium (DMEM) with 10% foetal bovine serum (FBS); M199 with 20% 
FBS; DMEM-F12 with 20% serum replacement, basic fibroblast growth factor and leukaemia 
inhibitory factor (SCM); endothelial growth medium (EGM); semi-solid MethoCult™; 
serum-free keratinocyte medium (K-SFM); and StemPro®-34. Effect on proliferation, 
morphology, protein and mRNA expression were evaluated. 
Results:  All media supported proliferation of CSSC with the exception of K-SFM and 
StemPro-34. Morphology differed between media: DMEM produced large cells whereas 
EGM produced very small cells. Culture in M199 produced a typical mesenchymal stem cell 
phenotype with high expression of CD105, CD90 and CD73 but not CD34. Culture in SCM 
produced a phenotype more reminiscent of a progenitor cell type with expression of CD34, 
ABCG2, SSEA-4 and PAX6.  
Discussion: Culture medium can significantly influence CSSC phenotype. SCM produced a 
cell phenotype closest to that of a pluripotent stem cell, and we considerate to be the most 
appropriate for development as a clinical grade medium for the production of CSSC 
phenotypes suitable for cell therapy. 
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Abbreviations 
α-SMA α-smooth muscle actin 
ALDH Aldehyde dehydrogenase 
bFGF Basic fibroblast growth factor 
BSA Bovine serum albumin 
CD Cluster of differentiation 
CSSC Corneal stroma-derived stem cells 
DAPI 4’,6-diamidino-2-phenylindole 
DMEM Dulbecco’s modified Eagle’s medium 
ECM Extracellular matrix 
EGF Epidermal growth factor 
EGM Endothelial growth medium 
FBS Foetal bovine serum 
hESC Human embryonic stem cells 
iPSC Induced pluripotent stem cells 
ISCT International Society for Cellular Therapy 
K-SFM Keratinocyte-serum free medium 
KSR Knockout serum replacement 
LIF Leukaemia inhibitory factor 
M199 Medium 199 
MSC Multipotent mesenchymal stromal cells 
PBS Phosphate buffered saline 
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PDGF Platelet-Derived Growth Factor 
RT Room temperature 
RT-qPCR Quantitative reverse transcription polymerase chain reaction 
SCM Stem cell medium 
TGF Transforming growth factor 
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Introduction 
Corneal blindness is one of the leading causes of treatable vision loss worldwide [1]. Trauma 
to the cornea can occur from a wide range of environmental factors including chemical 
agents, thermal and mechanical injuries, surgical intervention, and microbial infection [2, 3]. 
Specialised cellular and structural organization is responsible for corneal transparency 
essential for normal vision [4-6]. Due to this, the cornea poses unique therapeutic challenges. 
Chronic donor shortages, tissue quality issues, and complications with immune rejection have 
propelled the development of regenerative medicine strategies for the cornea. These new 
treatments include the development of stem cell therapies for the treatment of ocular surface 
disorders. 
The stroma of the cornea contains a population of cells known as keratocytes [7], which 
under normal healthy conditions remain quiescent and exhibit a dendritic morphology with 
extensive intercellular contacts [8, 9]. Keratocytes act to maintain the structure and 
transparency of the stroma by producing and maintaining extracellular matrix (ECM) 
proteins, such as collagen and proteoglycans [10-12]. Markers traditionally used to identify 
the keratocyte phenotype include aldehyde dehydrogenase (ALDH), keratocan, CD133 and, 
as originally identified by our group, CD34 [13-15]. 
Keratocytes can be isolated from the stroma using collagenase treatment for ex vivo culture. 
However, once transferred to tissue culture plastic, the cells differentiate, and alternative cell 
populations emerge, dependent on the culture environment [16-18]. The extracted stromal 
cells “activate” and take on a fibroblastic phenotype [19, 20]. In vivo, this “activation” is 
associated with response to injury, as the keratocytes adjacent to the wound begin to exhibit 
morphological characteristics of fibroblasts and commence tissue remodelling [5, 8]. In 
severe injuries or later stages of remodelling, a myofibroblast phenotype is adopted, which 
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actively secretes contractile ECM components, such as α-smooth muscle actin (α-SMA). This 
can cause scar formation and loss of corneal transparency [8, 21].  
In vitro, keratocytes extracted from the limbus, have been shown to display characteristics of 
multipotent mesenchymal stromal cells (MSC) [20, 22], that after several passages in a 
certain medium, conform to a criteria stipulated by the International Society for Cellular 
Therapy (ISCT) [18, 23]. The extracted corneal stroma-derived stem cells (CSSC) express 
MSC-associated cell surface markers such as CD29, CD73, CD90 and CD105, and possess 
the ability to differentiate down the osteogenic, chondrogenic and adipogenic lineages in 
vitro [18, 24]. Therefore, it has been hypothesized that the limbal keratocyte is an MSC 
progenitor found in the corneal stroma [18, 25]. A specific population of CSSC that can be 
identified by side population isolation has also been described that is believed to be a 
keratocyte progenitor [26].  
Cells extracted from the corneal stroma have previously been cultured under a number of 
different conditions, with the intention of either retaining keratocyte phenotype or promoting 
a stem cell phenotype. Traditionally, keratocytes have been cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% foetal bovine serum (FBS) [20, 27, 28], 
however this has been shown to produce sub-optimal culture conditions for the production of 
MSC [24]. Researchers have now expanded the repertoire of media that has been used for the 
culture of corneal stromal cells but few comparative studies between media have been 
performed. Culture in medium containing serum, of varying concentrations, is usually 
preferred. Serum has advantages as it provides a source of attachment and growth factors, 
allowing proliferation and rapid expansion of the cells. However, the presence of serum, or 
more specifically growth factors present in serum, such as transforming growth factor-β1 
(TGF-β1), are reported to cause fibroblastic or myofibroblastic differentiation, characterized 
by a fusiform morphology and protein markers such as α-SMA [29, 30] and CD90 [31] along 
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with the loss of keratocyte markers [5, 16]. Moreover, the addition of serum has been used to 
deliberately generate corneal fibroblasts rather than keratocytes [32], however, most 
researchers would prefer an undifferentiated/inactive phenotype. Cultures that contain a 
lower percentage of serum, such as 2% (v/v), retain a keratocyte phenotype more effectively, 
but have much lower proliferation rates [33]. It has also been suggested that serum-free 
growth media developed for other cell types might also be suitable, such as the use of 
keratinocyte serum free medium (K-SFM) [34]. Changing the basal medium from DMEM to 
medium 199 (M199) or DMEM/F12, which contain  a greater proportion of other 
components such as amino acids and nucleotides leads to the generation of a population of 
MSC or MSC-like cells [23, 35]. The use of M199 with the addition of 20% FBS to culture 
keratocytes, generates MSC that adhere to ISCT criteria [18]. Some researchers have cultured 
cells in media containing recombinant growth factors such as epidermal growth factor (EGF), 
basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF) and leukaemia 
inhibitory factor (LIF), in lieu of serum [32, 36, 37], in order to get a cell phenotype more 
indicative of a pluripotent stem cell. While this may prove more easily translatable to the 
clinic compared to serum, the addition of recombinant growth factors, both in research and 
clinically, can be costly. In addition, keratocytes express CD34 in vivo [14, 15], a marker 
commonly associated with haematopoietic stem cells, which might suggest that the use of 
culture media traditionally used to support cells of haematopoietic origin might be suitable. 
Herein, we compare the properties of cultured CSSC in seven different media formulations to 
identify the media that best promotes an in vitro stem cell phenotype. We investigate: two 
FBS-containing media, DMEM with 10% FBS and M199 with 20% FBS; a medium more 
associated with the culture of pluripotent stem cells containing bFGF and LIF (Stem Cell 
Medium, SCM); a medium designed for the growth of endothelial cells, but previously used 
for the culture of pluripotent stem cells (EGM) [38]; a serum-free medium (K-SFM); and two 
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media developed for the culture of haematopoietic cells, one semi-solid (MethoCult™) and 
one liquid (StemPro®-34). 
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Materials and Methods 
Tissue 
Human corneal tissue for research was obtained from Manchester or Bristol Eye Banks 
subject to a Materials Transfer Agreement. Use of human donor tissue was used with 
approval by the local ethics research committee and in accordance with the tenets of the 
Declaration of Helsinki, following consent obtained from the donors and/or their relatives. 
 
Isolation and culture of primary human corneal stromal stem cells 
Human corneal stromal stem cells (CSSC) were isolated from corneal rims, using a 
modification of a previously described method [23]. Excess sclera was removed and the 
epithelium and endothelium detached by gentle scraping. Remaining stromal tissue was 
divided into small pieces and digested in 1 mg/mL collagenase Type IA (Sigma Aldrich, 
Gillingham, UK) for 7 hours at 37°C. Digests were filtered through a 40 µm cell strainer 
before being centrifuged and resuspended in appropriate medium. CSSC were continually 
cultured in one of seven media types (table 1). CSSC from each donor were separated 
between all media, to allow for a true comparison of media effects, without donor-to-donor 
variation. Cells in all media were cultured on surfaces coated with 0.1% (v/v) gelatin (Sigma 
Aldrich) and incubated in a humidified environment at 37°C, 5% (v/v) CO2, with the 
respective medium changed every 2-3 days. Cells were passaged using treatment with 
TrypLE™ Express dissociation reagent and seeded at 3,000 cells/cm
2 
(Life Technologies, 
Paisley, UK).  
 
Cell proliferation and viability 
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Cell proliferation and viability was assessed by PrestoBlue™ Cell Viability Reagent (Life 
Technologies). Cells at passage 0 (P0) were seeded at 1000 cells/well in 96-well plates. On 
days 1, 3, 7, and 10 media was aspirated, cells washed in phosphate buffered saline (PBS), 
and 100 µL fresh medium applied. Subsequently, 10 µL PrestoBlue™ Cell Viability Reagent 
was added to each well and incubated for 20 minutes at 37°C. Aliquots of 100 µL were 
transferred to black 96-well plates and samples were rinsed in PBS and returned to culture in 
the appropriate medium. Fluorescence readings were taken at excitation 560 nm/emission 590 
nm using an Infinite® 200 Pro microplate reader (Tecan, Reading, UK) and results were 
corrected for background fluorescence from medium-only controls. Cell number was 
discerned by standard curve. 
 
Fluorescent immunocytochemistry 
Cell samples for immunocytochemistry were cultured in gelatin-coated glass chamber slides 
(Nunc Lab-Tek, Thermo Fisher Scientific, Loughborough, UK). Cells were fixed in a 4% 
(w/v) solution of buffered paraformaldehyde (Sigma Aldrich) for 10 minutes. After washing 
in PBS cells were permeabilised where appropriate, in 0.1% (v/v) Triton X-100 (Sigma 
Aldrich) for 5 minutes with subsequent washing in PBS. Blocking of non-specific protein 
binding was performed for 1 hour at room temperature (RT) in PBS with 1% (v/v) bovine 
serum albumin (BSA, Sigma Aldrich), 0.3 M glycine (Sigma Aldrich) and 3% (v/v) donkey 
serum (Sigma Aldrich). Samples were incubated with primary antibodies at 4°C overnight 
(see table 2 for antibody details). After washing with PBS, samples were incubated with 
secondary antibodies (table 2) for one hour at RT. Counterstaining with Alexa-Fluor 488 
conjugated phalloidin (dilution 1:40, New England Biolabs, Hitchin, UK) to stain F-actin was 
performed for 20 minutes at RT, before washing. Samples were also counterstained with 0.5 
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µg/mL 4’,6-diamidino-2-phenylindole (DAPI; Santa Cruz Biotechnology, Heidelberg, 
Germany) for 10 minutes. Chambers were removed and slides were mounted in fluorescence 
mounting medium (Dako, Ely, UK) before imaging. Negative controls were performed by 
omitting the primary antibody. 
Immunocytochemistry was quantified using Image J software version 1.46r. Total number of 
cells was determined using DAPI images. Image was converted to binary, a watershed was 
applied and the number of particles analysed, to calculate the number of stained nuclei. The 
number of antigen-positive cells were then determined manually using the inbuilt cell counter 
plugin, and a percentage of positive stained cells calculated. 
 
Microscopy and imaging 
Phase contrast imaging was performed on a Leica DM-IRB inverted microscope, and images 
captured with a Hammatsu digital camera and Volocity imaging software (Improvision, 
Coventry, UK). Fluorescent immunocytochemistry samples were cultured on glass chamber 
slides and viewed using an upright fluorescence microscope (BX51, Olympus, Southend-on-
Sea, UK) with images captured with a black and white camera (XM-10, Olympus) and 
Cell^F software (Olympus). 
 
Quantitative Reverse Transcription Polymerase Chain Reaction (RT-qPCR)   
Cells were lysed at P2 and the lysate was homogenized using QIAshredder columns (Qiagen, 
Manchester, UK). Total RNA was extracted using an RNeasy mini kit (Qiagen) according to 
manufacturer’s instructions. RNA quantity was measured using a NanoDrop 
spectrophotometer. 1 µg of RNA was transcribed into single stranded cDNA using 
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Superscript III reverse transcriptase (Life Technologies) with random hexamer primers, 
according to manufacturer’s instructions. For PCR reactions, 1 µL of cDNA was used with 
inventoried Taqman assays (Applied Biosystems, Life Technologies) to detect GAPDH 
(Hs99999905_m1), CD34 (Hs00990732_m1), THY1 (Hs00174816_m1), POU5F1 
(Hs00999634_gH), PAX6 (Hs00240871_m1), ALDH3A1 (Hs00964880_m1), ACTA2  
(Hs00909449_m1), KERA (Hs00559942_m1) and COL1A1 (Hs00164004_m1). Amplification 
was performed on an Mx3005P multicolour 96-well PCR system (Stratagene, Agilent 
Technologies, Stockport, UK). RT-qPCR reactions were analysed using the Real Time PCR 
Miner algorithm [39] which calculates efficiency and threshold cycle. All experimental 
values were normalised to readings of the endogenous reference gene GAPDH. 
 
Differentiation of CSSC to a keratocyte phenotype 
CSSC were grown in different media to P2 and subsequently seeded in 6-well plates and 
glass chamber slides at 20,000 cells/cm
2
. Cells were maintained in their respective culture 
media for 3 days before being changed to keratocyte differentiation media for 21 days. 
Keratocyte differentiation media consisted of DMEM/F12 supplemented with 50 µg/mL 
ascorbate 2-phosphate (Sigma-Aldrich), 10 µg/mL human insulin, 5.5 µg/mL human 
transferrin, 6.7 ng/mL sodium selenite (combination, Life Technologies), 1% non-essential 
amino acids (Life Technologies), 10 ng/mL bFGF (Life Technologies) and 20 ng/mL 
gentamicin, 0.5 ng/mL amphotericin B (Life Technologies). Non-differentiated controls were 
maintained in their culture media. 
 
Statistical Analysis 
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Statistical significances were analysed using GraphPad Prism version 6.02. One-way 
ANOVA was used to compare multiple groups with post-hoc Dunnett’s multiple comparison 
test. 
 
.  
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Results 
Effect of different media on proliferation of CSSC 
Effects of the seven media on CSSC proliferation and viability were tested at P0 (figure 1). 
CSSC proliferation was slow in standard DMEM over 10 days (figure 1b). Considerably 
higher proliferation rates were seen in M199 (figure 1c), SCM (figure 1d) and EGM (figure 
1e). However, in EGM, viability dropped after day 7, when the cells reached confluence. 
Cells cultured in MethoCult (figure 1f) adhered to the bottom of the well, despite the semi-
solid medium and divided slowly, not proliferating significantly until after day 7. Cells in K-
SFM did not proliferate at all, but there were still viable cells at day 10. The StemPro-34 
medium did not support CSSC proliferation, as there were no viable cells adhered to the plate 
by day 7. 
  
Effects of different media on morphology of CSSC 
Effects of the seven initial media types were compared by imaging CSSC morphology at P0, 
after 5 days of culture in the respective media (figure 2). Phase contrast imaging showed that 
there were subjectively lower numbers of cells in DMEM (a) and MethoCult (e) than M199 
(b), SCM (c) and EGM (d). There were very few cells in K-SFM (f) and in StemPro-34 (g), 
the cells had begun to become rounded and detach from the plate, a process commonly seen 
with loss of viability. F-actin (figure 2B) and vimentin (figure 2C) staining demonstrated 
differences in morphology between the cell cultures. Cells in M199 and EGM began to align 
spontaneously with each other. Cells cultured in DMEM were much larger and spread over a 
greater area. Cells cultured in M199 had strong vimentin staining with filaments circling the 
nucleus and actin filaments at the cell periphery and stretched across the cell. Cells in SCM 
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were smaller than M199, and appeared to contain a higher proportion of actin fibres. Cells in 
EGM were the smallest cells, had aligned with each other and did not have vimentin rings 
around the nucleus. When cultured in MethoCult, CSSC had a more heterogenous appearance 
with cells of many sizes. CSSC in both K-SFM and StemPro-34 were sparse, individual cells 
displaying a vimentin and actin cytoskeleton. However, there were too few cells in these 
media to determine differences in morphology. Low magnification images of actin/vimentin 
indicated the density of the cell monolayer, with M199 and SCM having the densest 
monolayers at day 7. 
 
Effect of different media on protein expression of CSSC 
CSSC at P2 were seeded in glass chamber slides and immunocytochemistry was performed to 
identify expression of key markers associated with MSC, keratocytes and pluripotent stem 
cells. Images were then quantified to estimate the purity of the cell populations in each 
media. The medium StemPro-34 was not included due to the previously demonstrated rapid 
loss of cell viability. Figure 3 shows the expression of cluster of differentiation (CD) markers 
positively and negatively associated with MSC. Figure 4 shows the quantification of these 
markers. CD34 expression is typically considered a marker absent on MSC; however, it is 
also a keratocyte marker. CD34 expression can clearly be seen in individual cells in EGM 
and K-SFM, and in a number of cells in SCM. CD34 staining was not observed in DMEM, 
M199 and MethoCult. CD105, CD90 and CD73 are markers of MSC. The percentage of cells 
expressing CD34 was significantly higher in SCM and K-SFM than all other media and when 
quantified, CD34 was stained in approximately 55.2% cells in SCM and 72.7% cells in K-
SFM (figure 4A). CD105 was observed on all cells in all media and the merged image with 
CD34 shows the individual cells that are expressing CD34 also express CD105. There were 
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no significant differences between percentages of cells expressing CD105 in different media, 
with nearly 100% of cells expressing CD105 in each media (figure 4B). CD90 staining was 
strong in M199, SCM and K-SFM. However, it was not present in EGM and only appeared in 
some cells in DMEM and MethoCult. Quantification of the percentage of cells stained for 
CD90 revealed that there were significantly higher numbers in M199 (97.4%), SCM (99.8%) 
and K-SFM (97.4%), than DMEM (46.8%), EGM (36.8%) and MethoCult (71.1%). CD73 
was seen in all cells in every medium and all media had approximately 100% of cells staining 
for CD73 
Immunocytochemistry was performed for a range of other markers associated with 
keratocytes and stem cells (figure 5) and subsequently quantified (figure 6). ABCG2 was 
detected in over 80% of cells in SCM (90.2%), EGM (98.5%), MethoCult (87.1%) and K-
SFM (83.3%), and to a lesser degree in the FBS-containing media DMEM (62.9%) and M199 
(11.6%). Keratocan, a proteoglycan secreted by keratocytes, was detected in all cultures; 
however higher levels of staining were seen in cell cultured in DMEM (93.3%), EGM 
(81.0%), MethoCult (62.8%)and K-SFM (90.3%), than in SCM (36.8%) and M199 (10.6%). 
SSEA-4, a cell surface marker found on pluripotent stem cells was seen to a high degree in 
SCM (72.4%) and EGM (75.0%) but to a lesser degree in DMEM (37.5%), M199 (13.3%), 
MethoCult (9.0%)and K-SFM (12.0%).  Oct-4A, a transcription factor associated with 
pluripotent stem cells was seen in almost all the nuclei of cells cultured in M199 (93.8%), 
SCM (94.1%), EGM (92.3%)and MethoCult (96.1%), but in only half of DMEM (51.6%) 
and very few in K-SFM (5.6%). PAX6 was seen predominantly in SCM (86.8%), EGM 
(98.5%), MethoCult (68.2%) and K-SFM (76.7%). 
 
Effect of different media on mRNA expression of CSSC 
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RT-qPCR was performed on CSSC at P2 to determine relative differences in mRNA level of 
CD34, THY1 (gene name for CD90), POU5F1 (gene name for Oct-4) and PAX6 (figure 7). 
CD34, THY1 and PAX6 mRNA level was significantly higher in SCM than in any other 
medium. For CD34 and THY1 there were no other significant differences in mRNA levels 
between DMEM, M199, EGM and MethoCult. POU5F1 was downregulated in MethoCult 
compared to DMEM, but no differences were seen between the other media. PAX6 was 
downregulated in M199, EGM and MethoCult, when compared to DMEM. 
 
Effect of differentiation on keratocyte differentiation 
CSSC that had been cultured in different media up to P2 were changed to a serum-free 
keratocyte differentiation media for 21 days. Immunocytochemistry and RT-qPCR were 
performed to assess levels of differentiation compared to non-differentiated controls (figure 
8). Immunocytochemistry showed increased levels of ALDH3A1 in all media (fig. 8A vi-x). 
However, CSSC, in SCM, EGM and MethoCult appeared to contain higher levels of 
ALDH3A1 in the non-differentiated controls (fig. 8A i-v). Myofibroblast marker α-SMA was 
present in both the control and differentiated samples in DMEM (fig. 8B i/vi) and M199 (fig. 
8B ii/vii). Non-differentiated controls in SCM contained some cells expressing α-SMA (fig. 
8Biii) but these were not present in the differentiated sample (fig. 8Bviii). CSSC cultured in 
EGM media, showed the reverse, with no staining for α-SMA in control samples (fig. 8Biv) 
but increased staining in the differentiated samples (fig. 8Bix). No α-SMA was seen in 
MethoCult samples. Staining for CD34 was increased in the differentiation samples for all 
media (fig. 8C vi-x). However, SCM controls also contained some cells that stained for 
CD34. RT-qPCR showed that ALDH3A1 was significantly increased in differentiated CSSC 
from DMEM, M199, and SCM culture compared to controls, but not in EGM or MethoCult 
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(fig. 8D). ACTA2 (gene name for α-SMA) was significantly increased in both DMEM and 
EGM cells when differentiated, and was not significantly decreased in differentiated cells 
from any media (fig. 8E). CD34 expression was increased in differentiated cells in all media, 
but only significantly in SCM and MethoCult (fig. 8F). Increased mRNA levels of KERA 
(gene name for keratocan, fig. 8G) and COL1A1 (collagen-I, fig. 8H) were seen in 
differentiated cells from all media, but were increased significantly in cells propagated in 
SCM, EGM and MethoCult, indicating increased ECM production. 
 
Discussion 
Corneal reconstruction with amniotic membrane [40, 41] has demonstrated that the acellular 
amniotic stroma is repopulated by corneal keratocytes that migrate from the stroma through 
breaks in the Bowman’s membrane. These cells are initially CD34 negative but α-SMA and 
vimentin positive, indicating that they are an “activated” phenotype. When corneal buttons 
were obtained from corneal grafts performed around 9 to 12 months subsequent to the 
amniotic membrane graft, several cells in the amnion stroma were positive for CD34, 
indicating that immunophenotypical transitions occur over time during corneal regeneration 
in vivo [40]. This holds promise for use of in vitro expanded CSSC in cell therapies for 
corneal regeneration.  
As the potential for the application of regenerative cell therapies for the cornea is realised and 
research gathers momentum, it is essential that common denominators are established in 
relation to methodology, so that outcomes are comparable and understood by all. Culture 
media constituents and respective concentrations can influence cell behaviour and 
differentiation. Hence, even if we start with an identical cell population, different media and 
culture environments will result in different cell populations after extended culture, although 
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most or all are collectively referred to as ‘progenitor or stem cells’. This study, wherein a 
comprehensive comparison of CSSC media was undertaken concerning cell morphology, 
proliferation, protein and gene expression, and keratocyte differentiation ability addresses this 
issue by identifying an optimal medium and an optimal in vitro progenitor cell phenotype, 
with the potential to generate keratocytes. For the purposes of this study, we considered an 
optimal culture medium to have the following properties: the ability to maintain viability and 
proliferation of the CSSC in a moderate manner; the promotion of stem cell characteristics 
including typical markers for progenitor and pluripotent stem cells; and the ability to allow 
differentiation back to a keratocyte phenotype. If the cell were to become part of a cell therapy, the 
optimal medium would also need to allow easy transition to a clinical manufacturing process. For this 
reason, media containing FBS would be unsuitable due to its animal origin and variable non-defined 
composition.  
Our results demonstrate that when an extracted cell population is divided into different 
media, the resulting cultured cell populations show very different characteristics. Although, 
some markers such as vimentin, ALDH3A1, CD73 and CD105 were conserved across all 
media, these markers are associated with fibroblasts and MSC and may potentially be 
induced by culture on two-dimensional plastic surfaces. This also suggests that the cells 
fundamentally express a range of baseline markers in vitro, but changing the medium or 
supplements can cause additional markers to be either maintained or expressed, such as 
ABCG2, CD34 and PAX6. 
Previous media comparison studies have focused solely on the production and maintenance 
of an MSC phenotype in CSSC [23, 24], as defined by the ISCT [42]. However, the current 
minimal criteria for MSC are not ideal for assessing the phenotype of CSSC, as one criterion 
states that MSC should not express CD34. Nevertheless, our group has showed CD34 is a 
well-established marker for quiescent keratocytes in vivo [14, 15], and CD34 has been linked 
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to the stem-cell properties of CSSC and other potentially related cell types [23, 43]. The 
function of CD34 expression in keratocytes has not yet been elucidated, although it has been 
speculated that CD34 plays roles in regulation of differentiation, adhesion and quiescence 
[14, 43]. It has been suggested that CD34
+
 keratocytes are of hematopoietic origin [27], 
however, these cells do not form hematopoietic colonies when cultured in semi-solid 
medium, as shown by culture in MethoCult in this study, and in reality display a plastic 
adherent, fibroblastic morphology [18]. For these reasons, a medium that satisfies the 
minimum criteria for an MSC phenotype, such as M199, may not be as desirable for culture 
of CSSC as, for example SCM, a medium that promotes markers associated with an MSC 
phenotype (CD73, CD90, CD105), alongside other progenitor/stem cell markers, such as 
CD34, ABCG2, PAX6, Oct-4, and SSEA-4.     
ABCG2 is a molecular determinant of the side population phenotype that is characteristic of 
stem cells, and has been used previously to identify CSSC [26, 44]. ABCG2 is expressed by a 
wide variety of stem cells including haematopoietic stem cells [45], embryonic stem cells 
[46], neural stem cells [47], and perhaps most relevantly limbal epithelial stem cells [48]. 
ABCG2 is often downregulated during stem cell differentiation [44], suggesting that it plays 
a regulatory role in maintaining stem cells in an undifferentiated state.  PAX6, although not 
conventionally a stem or progenitor marker, is strongly associated with eye development. 
PAX6 has also been associated with keratocyte progenitors [49]. SSEA-4 and OCT-4 are 
markers that are used to identify human pluripotent stem cells [50]. However, these markers 
have also been found on adult stem cells including MSC [51]. The presence of all these 
markers on the cells in SCM suggests a level of plasticity, which more differentiated cells 
may not possess. This plasticity will allow the exploitation of CSSC as cellular therapies, 
either to repopulate the corneal stroma as keratocytes, or in broader regenerative medicine 
areas, as they are a readily available and easy to isolate stem cell source. 
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Many researchers are aiming to use CSSC as part of regenerative cellular therapies. For this 
purpose, CSSC would need to be expanded in large quantities whilst maintaining the desired 
phenotype. This would rule out the use of any medium similar to K-SFM or StemPro-34. 
DMEM and MethoCult also had slow proliferation rates, so it would be unlikely that media 
similar to either of these would be used. The use of DMEM in particular, seemed to favour a 
characteristic fibroblastic phenotype, with very large cells and low expression of CD34, 
CD90, ABCG2 and SSEA-4. Cells in MethoCult had a more heterogeneous appearance that 
may have signified different populations of differentiating cells potentially caused by the 
inclusion of factors such as interleukin-3 and erythropoietin in the medium. Growth factors 
such as bFGF, PDGF, and isoforms of TGF-β have all been associated with regulation of 
wound healing and a keratocyte phenotype in the corneal stroma [52, 53]. 
Ingredients within a basal medium can have a large effect on the final cell phenotype. 
Comparisons between the DMEM and M199 formulations reveals that M199 contains a 
number of constituents not found in DMEM including numerous pyrimidines and purines 
including ATP, ribose, cholesterol and vitamins which likely drive proliferation [54]. M199 
contains the same amount of D-glucose as DMEM ‘low glucose’ formulations (1000 mg/L) 
whereas the ‘high glucose’ DMEM used in this study contains significantly higher 
concentrations (4500 mg/L). This indicates that the much faster proliferation rates seen in 
M199 compared to DMEM was not down to glucose concentration. 
The success of SCM in promoting markers associated with progenitor cells and pluripotency 
is most likely because it is a medium predominantly used in the culture of human embryonic 
stem cells (hESC) and induced pluripotent stem cells (iPSC). SCM does not contain FBS but 
instead uses knockout serum replacement (KSR). In cultures of hESC and iPSC, FBS is not 
suitable as it is an undefined biological product, which varies from batch-to-batch, and can 
trigger spontaneous differentiation of cells. KSR is chemically defined and the composition 
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can be found in its patent [55] and in this publication by Garcia-Gonzalo and Belmonte [56]. 
KSR predominantly contains a mix of amino acids, vitamins, antioxidants, trace elements, 
insulin, transferrin and lipid-rich albumin, which has been shown to be the ingredient most 
involved in regulation of pluripotency [56]. SCM also contains the recombinant proteins 
bFGF and LIF. bFGF is associated with differentiation to the keratocyte phenotype [57] and 
is essential for the maintenance of pluripotency of hESC [58]. LIF is a factor that is essential 
in the maintenance of pluripotency in mouse ESC [59] but has also been identified as 
important in naïve hESC [60]. The combination of these ingredients may allow SCM to 
induce or maintain a naïve or progenitor phenotype within the CSSC population. SCM was 
the most successful propagation medium in studies assessing the ability to differentiate back 
to a keratocyte in vitro. This may be because SCM retained markers associated with the 
keratocyte phenotype more successfully than the other media types.  
From those tested, we have identified SCM as being the medium with the most potential for 
cell therapy applications; however in its current form it would still not be ideal for the clinical 
production of CSSC as it is not completely free of animal derived products (xeno-free). 
However, all the ingredients have available xeno-free alternatives, which are currently 
expensive, and would add to the cost of research and clinical translation. It is also worth 
noting that although the culture medium is important in deriving a phenotype of choice; other 
aspects of in vitro cell culture can have an effect. Culturing in a three-dimensional 
environment rather than two-dimensional can help to dedifferentiate cells back to their 
original form [61], thus changing to a scaffold based culture method may have an additional 
effect on top of culture medium. Other changes to the environment can include the use of 
hypoxia, which has been shown to induce faster proliferation whilst maintaining stem cell 
potential and delaying the cellular ageing process [62]. However, culture in a three-
dimensional environment can be complicated and have many unpredictable effects on the 
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cells, and a hypoxic environment has been shown to promote chondrogenic differentiation, 
which may be an issue as the cells are of mesenchymal origin [63, 64]. 
This study has shown that there can be considerable variation in the properties of CSSC when 
cultured in different media. This indicates that in many cases, studies between groups may 
not be comparable if performed in different media, due to induced variations in final 
phenotype. For the eventual aim of producing a cell therapy from CSSC, it will be imperative 
to find a medium that supports a stem cell phenotype and in which the cells can be stably 
expanded and maintained as stocks in tissue banks, for release when required for clinical use. 
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Table 1. Details of experimental culture media.  
Medium  Basal 
Medium 
Supplements Reference 
DMEM Dulbecco’s 
Modified 
Eagle’s 
Medium 
(Gibco, Life 
Technologies) 
10% (v/v) foetal bovine serum (Sigma 
Aldrich) 
2 mM L-glutamine (Sigma Aldrich) 
20 ng/mL gentamicin, 0.5 ng/mL 
amphotericin B (Life Technologies) 
[20, 27, 28] 
M199  Medium 199 
(Sigma 
Aldrich) 
20% (v/v) foetal bovine serum 
2 mM L-glutamine 
20 ng/mL gentamicin, 0.5 ng/mL 
amphotericin B 
[18, 23] 
Stem Cell 
Medium 
(SCM) 
DMEM/F12 
(Gibco, Life 
Technologies) 
20% (v/v) knock-out serum replacement 
(KSR, Life Technologies) 
1% (v/v) non-essential amino acids (NEAA, 
Life Technologies) 
4 ng/mL bFGF (Life Technologies) 
5 ng/mL hLIF (New England Biolabs, UK) 
20 ng/mL gentamicin, 0.5 ng/mL 
amphotericin B (Life Technologies) 
[36, 37] 
Endothelial 
Growth 
Media 
(EGM) 
EBM-2 Basal 
Medium 
(Lonza, 
Belgium) 
EGM-2 SingleQuot Kit (CC-4147, Lonza) [38] 
MethoCult™ MethoCult® 
H4034 
Optimum 
(STEMCELL 
Technologies, 
UK) 
20 ng/mL gentamicin, 0.5 ng/mL 
amphotericin B (Life Technologies) 
[65] 
Keratinocyte 
Serum Free 
Medium (K-
SFM) 
Keratinocyte-
SFM  
(Life 
Technologies) 
Keratinocyte Supplement (Bovine Pituitary 
Extract, Epidermal Growth Factor (EGF), 
Life Technologies) 
20 ng/mL gentamicin, 0.5 ng/mL 
amphotericin B (Life Technologies) 
[24, 34] 
StemPro®-
34 
StemPro®-34 
Serum Free 
Medium  
(Life 
Technologies 
StemPro®-34 Nutrient Supplement 
20 ng/mL gentamicin, 0.5 ng/mL 
amphotericin B (Life Technologies) 
[66] 
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Table 2. Details of antibodies used in immunocytochemistry 
Antigen Clone  Source  (Catalogue #) Host Conjugate 
Vimentin V9 Vector Labs (VPV684) Mouse - 
CD34 QBEND10 Abcam (Ab8536) Mouse - 
CD105 Polyclonal R&D Systems (AF1097) Goat - 
CD90 F15-42-1 Thermo Scientific Pierce (MA5-
16671) 
Mouse - 
CD73 Polyclonal Abcam (Ab71322) Rabbit - 
ABCG2 5D3 R&D Systems (MAB995) Mouse - 
ALDH3A1 Polyclonal Abcam (ab76976) Rabbit - 
Keratocan Polyclonal Santa Cruz Biotechnology (sc-
33243) 
Goat - 
SSEA-4 MC813-70 R&D Systems (MAB1435) Mouse - 
α-SMA 1A4 Abcam (ab7817) Mouse - 
Oct-4A 653108 R&D Systems (MAB17591) Mouse - 
PAX6 Polyclonal Thermo Scientific Pierce (PA5-
25970) 
Rabbit  
Mouse IgG Polyclonal Life Technologies (A-21202) Donkey Alexa 
Fluor-488 
Goat IgG Polyclonal Life Technologies (A-11056) Donkey Alexa 
Fluor-546 
Rabbit IgG Polyclonal Life Technologies (A-10040) Donkey Alexa 
Fluor-546 
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Figure Legends 
Figure 1. Effect of culture medium on proliferation of CSSC. Cells were cultured in (a) 
DMEM (b) M199 (c) SCM (d) EGM (e) MethoCult (f) K-SFM (g) StemPro-34. Graph shows 
number of P0 cells cultured in different media at day 1, 3, 7 and 10. Data shown as mean 
±SEM of 3 independent experiments each with 3 replicates (n=3). 
Figure 2. Effect of culture medium on morphology and cytoskeletal arrangements of 
CSSC. Cells were cultured in (a) DMEM (b) M199 (c) SCM (d) EGM (e) MethoCult (f) K-
SFM (g) StemPro-34. (A) Phase contrast images at day 5 (scale bar=90 µm). (B) F-Actin 
(green) staining counterstained with DAPI (blue) (scale bar=100 µm). (C) Vimentin (red) 
staining counterstained with DAPI (blue) (scale bar=100 µm). (D) Merged F-Actin, vimentin, 
DAPI staining taken at low magnification (x40, scale bar=500 µm). 
Figure 3. Effect of culture medium on mesenchymal stem cell markers. Cells were 
cultured in (A) DMEM (B) M199 (C) SCM (D) EGM (E) MethoCult (F) K-SFM. 
Immunocytochemistry was performed for (a) CD34, green; (b) CD105, red; (c) CD90, green; 
and (d) CD73, red. Negative control images (secondary antibody only) of (e) donkey anti-
mouse IgG Alexa Fluor-488, (f) donkey anti-goat IgG Alexa Fluor-546 (g) donkey anti-rabbit 
IgG Alexa Fluor-546. All images shown with DAPI counterstain (blue), scale bar=100 µm. 
Figure 4. Quantification of number of cells expressing mesenchymal stem cells markers. 
Immunocytochemistry images were quantified to calculate the number of cells in each media 
expressing (A) CD34, (B) CD105, (C) CD90 and (D) CD73. Data shown as mean±SD of 3 
independent experiments (n=3). Statistical significances comparing each media to each other 
are shown in the table below each graph: ns, non-significant, *p≤0.05, **p≤0.01, 
***p≤0.001, ****p≤0.0001 (one-way ANOVA). 
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Figure 5. Effect of culture medium on pluripotency and keratocyte markers. Cells were 
cultured in (A) DMEM (B) M199 (C) SCM (D) EGM (E) MethoCult (F) K-SFM. 
Immunocytochemistry was performed for (a) ABCG2, green; (b) Keratocan, green; (c) 
SSEA-4, green; (d) Oct-4A, red and (e) Pax6, red. Negative controls (secondary antibody 
only) can be seen in figure 3. All images shown with DAPI counterstain (blue), scale bar=100 
µm. 
Figure 6. Quantification of cell number expressing pluripotency and keratocyte 
markers. Immunocytochemistry images were quantified to calculate the number of cells in 
each media expressing (A) ABCG2, (B) Keratocan, (C) SSEA-4, (D) Oct-4A and (E) Pax6. 
Data shown as mean±SD of 3 independent experiments (n=3). Statistical significances 
comparing each media to each other are shown in the table below each graph: ns, non-
significant, *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001 (one-way ANOVA). 
Figure 7. Comparative effect of culture medium on gene expression of CSSC. CSSC 
were continually cultured in DMEM, M199, SCM, EGM or MethoCult to P2. Relative levels 
of mRNA were determined by RT-qPCR for the following genes (a) CD34 (b) THY1, (c) 
POU5F1 and (d) PAX6. Expression of each target gene is normalised to GAPDH and 
represented relative to mRNA expression in DMEM. Data shown as mean±SEM of 3 
independent experiments (n=3), each with 3 replicates. Statistical significance vs. DMEM 
*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001 (one-way ANOVA). 
Figure 8. Effect of culture medium on differentiation back to a keratocyte phenotype. 
CSSC at P3 were differentiated back to a keratocyte phenotype using a serum-free medium 
containing bFGF, for 21 days. Immunocytochemistry was performed for (A) ALDH3A1, (B) 
α-SMA, (C) CD34 on non-differentiated control samples (i-v) and differentiated samples (vi-
x). CSSC had ben propagated in DMEM, M199, SCM, EGM or MethoCult prior to 
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differentiation. All images shown with DAPI counterstain (blue), scale bar=100 µm. Relative 
levels of mRNA were determined by RT-qPCR for the following genes (D) ALDH3A1 (E) 
ACTA2 (F) CD34 (G) KERA and (H) COL1A1. Expression of each target gene is normalised 
to GAPDH and represented relative to mRNA expression in the non-differentiated control of 
that media. Data shown as mean±SEM of 3 independent experiments (n=3), each with 2 
replicates. Statistical significance vs. control *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001 
(two-way ANOVA). 
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Figure 1. Effect of culture medium on proliferation of CSSC. Cells were cultured in (a) DMEM (b) M199 (c) 
SCM (d) EGM (e) MethoCult (f) K-SFM (g) StemPro-34. Graph shows number of P0 cells cultured in different 
media at day 1, 3, 7 and 10. Data shown as mean ±SEM of 3 independent experiments each with 3 
replicates (n=3).  
119x144mm (300 x 300 DPI)  
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Figure 2. Effect of culture medium on morphology and cytoskeletal arrangements of CSSC. Cells were 
cultured in (a) DMEM (b) M199 (c) SCM (d) EGM (e) MethoCult (f) K-SFM (g) StemPro-34. (A) Phase 
contrast images at day 5 (scale bar=90 µm). (B) F-Actin (green) staining counterstained with DAPI (blue) 
(scale bar=100 µm). (C) Vimentin (red) staining counterstained with DAPI (blue) (scale bar=100 µm). (D) 
Merged F-Actin, vimentin, DAPI staining taken at low magnification (x40, scale bar=500 µm).  
140x104mm (300 x 300 DPI)  
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Figure 3. Effect of culture medium on mesenchymal stem cell markers. Cells were cultured in (A) DMEM (B) 
M199 (C) SCM (D) EGM (E) MethoCult (F) K-SFM. Immunocytochemistry was performed for (a) CD34, 
green; (b) CD105, red; (c) CD90, green; and (d) CD73, red. Negative control images (secondary antibody 
only) of (e) donkey anti-mouse IgG Alexa Fluor-488, (f) donkey anti-goat IgG Alexa Fluor-546 (g) donkey 
anti-rabbit IgG Alexa Fluor-546. All images shown with DAPI counterstain (blue), scale bar=100 µm.  
119x195mm (300 x 300 DPI)  
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Figure 4. Quantification of number of cells expressing mesenchymal stem cells markers. 
Immunocytochemistry images were quantified to calculate the number of cells in each media expressing (A) 
CD34, (B) CD105, (C) CD90 and (D) CD73. Data shown as mean±SD of 3 independent experiments (n=3). 
Statistical significances comparing each media to each other are shown in the table below each graph: ns, 
non-significant, *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001 (one-way ANOVA).  
80x59mm (300 x 300 DPI)  
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Figure 5. Effect of culture medium on pluripotency and keratocyte markers. Cells were cultured in (A) DMEM 
(B) M199 (C) SCM (D) EGM (E) MethoCult (F) K-SFM. Immunocytochemistry was performed for (a) ABCG2, 
green; (b) Keratocan, green; (c) SSEA-4, green; (d) Oct-4A, red and (e) Pax6, red. Negative controls 
(secondary antibody only) can be seen in figure 3. All images shown with DAPI counterstain (blue), scale 
bar=100 µm.  
119x179mm (300 x 300 DPI)  
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Figure 6. Quantification of cell number expressing pluripotency and keratocyte markers. 
Immunocytochemistry images were quantified to calculate the number of cells in each media expressing (A) 
ABCG2, (B) Keratocan, (C) SSEA-4, (D) Oct-4A and (E) Pax6. Data shown as mean±SD of 3 independent 
experiments (n=3). Statistical significances comparing each media to each other are shown in the table 
below each graph: ns, non-significant, *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001 (one-way ANOVA). 
99x109mm (300 x 300 DPI)  
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Figure 7. Comparative effect of culture medium on gene expression of CSSC. CSSC were continually cultured 
in DMEM, M199, SCM, EGM or MethoCult to P2. Relative levels of mRNA were determined by RT-qPCR for 
the following genes (a) CD34 (b) THY1, (c) POU5F1 and (d) PAX6. Expression of each target gene is 
normalised to GAPDH and represented relative to mRNA expression in DMEM. Data shown as mean±SEM of 
3 independent experiments (n=3), each with 3 replicates. Statistical significance vs. DMEM *p≤0.05, 
**p≤0.01, ***p≤0.001, ****p≤0.0001 (one-way ANOVA).  
62x48mm (300 x 300 DPI)  
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Figure 8. Effect of culture medium on differentiation back to a keratocyte phenotype. CSSC at P3 were 
differentiated back to a keratocyte phenotype using a serum-free medium containing bFGF, for 21 days. 
Immunocytochemistry was performed for (A) ALDH3A1, (B) α-SMA, (C) CD34 on non-differentiated control 
samples (i-v) and differentiated samples (vi-x). CSSC had ben propagated in DMEM, M199, SCM, EGM or 
MethoCult prior to differentiation. All images shown with DAPI counterstain (blue), scale bar=100 µm. 
Relative levels of mRNA were determined by RT-qPCR for the following genes (D) ALDH3A1 (E) ACTA2 (F) 
CD34 (G) KERA and (H) COL1A1. Expression of each target gene is normalised to GAPDH and represented 
relative to mRNA expression in the non-differentiated control of that media. Data shown as mean±SEM of 3 
independent experiments (n=3), each with 2 replicates. Statistical significance vs. control *p≤0.05, 
**p≤0.01, ***p≤0.001, ****p≤0.0001 (two-way ANOVA).  
95x150mm (300 x 300 DPI)  
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